{"id":"W7108732077","doi":"10.1182/blood-2025-151","title":"3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; McGill University; University of Toronto; Cargill (Canada)","funders":"","keywords":"Brentuximab vedotin; Nivolumab; Hodgkin lymphoma; Dacarbazine; Clinical endpoint; Stage (stratigraphy); Randomized controlled trial; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001648346,0.0003969341,0.0009887876,0.0002277324,0.0002654671,0.000496424,0.000300086,0.0005296567,0.002322413],"category_scores_gemma":[0.0006578564,0.0001902868,0.0007733289,0.0002369509,0.0002964564,0.0003445279,0.0002225874,0.0007977347,0.0004398639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003860912,"about_ca_system_score_gemma":0.0003619406,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004090786,"about_ca_topic_score_gemma":0.000742447,"domain_scores_codex":[0.9996191,0.0001627808,0.00002975491,0.00007695192,0.00004441213,0.00006693311],"domain_scores_gemma":[0.9993039,0.0001286118,0.0001938485,0.00007633861,0.00005132719,0.0002459867],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7560394,0.01304693,0.1205074,0.0003660776,0.001816763,0.0004924755,0.0002386305,0.001541859,0.03657894,0.0001270208,0.003087641,0.06615692],"study_design_scores_gemma":[0.1002076,0.5238833,0.3568649,0.00006732107,0.001711624,0.001080236,0.0001055377,0.001738031,0.007992011,0.0001750563,0.006136234,0.00003802582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981263,0.0005499734,0.0001418719,0.00004396937,0.00002139735,0.00009258877,0.0005417661,0.00001345725,0.0004686129],"genre_scores_gemma":[0.9980291,0.0001443835,0.0001111171,0.00007611445,0.00003482664,0.00008664032,0.001028161,0.000004289127,0.0004852884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002322413,"threshold_uncertainty_score":0.008717418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01148639022516747,"score_gpt":0.2751201723404266,"score_spread":0.2636337821152592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}